Adenylosuccinate Lyase Deficiency (ADSL deficiency / ASLD): Comprehensive Disease Characteristics Report

Executive summary

Adenylosuccinate lyase deficiency (also called adenylosuccinase deficiency; ADSL deficiency; ASLD) is an ultra-rare, autosomal recessive inborn error of purine metabolism caused by biallelic pathogenic variants in ADSL, leading to reduced adenylosuccinate lyase activity in de novo purine synthesis and the purine nucleotide cycle and accumulation of the succinylpurine metabolites SAICAr and succinyladenosine (S‑Ado) in extracellular fluids. Clinical presentation is predominantly neurologic and includes developmental delay/intellectual disability, hypotonia, epilepsy (often intractable), microcephaly, and autistic features, with a spectrum from fatal neonatal encephalopathy to milder later-onset disease. (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, donti2016diagnosisofadenylosuccinate pages 1-2, cutillo2024electroclinicalfeaturesand pages 1-2)

1. Disease information

1.1 Definition and overview

A widely cited review defines the disorder as a purine metabolism defect with characteristic metabolite accumulation: “Biochemically this defect manifests by the presence in the biologic fluids of two dephosphorylated substrates of ADSL enzyme: succinylaminoimidazole carboxamide riboside (SAICAr) and succinyladenosine (S-Ado).” (Journal of Inherited Metabolic Disease, online 2014; print Aug 2015) (jurecka2015adenylosuccinatelyasedeficiency pages 1-3).

1.2 Key identifiers

Table: This table summarizes the core disease identifiers and commonly used synonyms for adenylosuccinate lyase deficiency. It is useful for harmonizing nomenclature across OMIM, MONDO, clinical trial records, and literature sources.

Additional identifiers not confirmed in retrieved full-text: Orphanet (ORPHA ID), ICD-10/ICD-11 codes, and MeSH Unique ID (UID) were not explicitly present in the retrieved literature text; these should be verified in Orphanet/ICD/MeSH browsers and then mapped to the knowledge base entry.

1.3 Common synonyms

• Adenylosuccinate lyase deficiency; ADSL deficiency (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, donti2016diagnosisofadenylosuccinate pages 1-2)
• ASLD (used in 2023 model-organism literature) (moro2023adenylosuccinatelyasedeficiency pages 1-2, fenton2023acaenorhabditiselegans pages 1-3)
• Adenylosuccinase deficiency (historical enzyme-based synonym) (fenton2023acaenorhabditiselegans pages 15-16)

1.4 Evidence source types

• Aggregated disease-level resources/reviews: JIMD 2015 review; Metabolites 2023 review (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, camici2023inbornerrorsof pages 9-11)
• Human clinical cohort/long-term follow-up: Epilepsia Open 2024 cohort + literature appraisal (cutillo2024electroclinicalfeaturesand pages 1-2, cutillo2024electroclinicalfeaturesand pages 2-4)
• Human diagnostic method papers: plasma metabolomics diagnosis paper (2016) (donti2016diagnosisofadenylosuccinate pages 1-2, donti2016diagnosisofadenylosuccinate pages 3-4)
• Interventional clinical research: allopurinol phase 2 trial registered at ClinicalTrials.gov (NCT03776656 chunk 1, NCT03776656 chunk 2)
• Model organism: C. elegans mechanistic disease models (2023) (moro2023adenylosuccinatelyasedeficiency pages 1-2, fenton2023acaenorhabditiselegans pages 1-3)

2. Etiology

2.1 Disease causal factors

Primary cause: biallelic pathogenic variants in ADSL causing reduced adenylosuccinate lyase function and accumulation of succinylpurines. The disorder is described as “a rare autosomal recessive neurometabolic disorder” caused by loss of ADSL enzymatic activity (donti2016diagnosisofadenylosuccinate pages 1-2, jurecka2015adenylosuccinatelyasedeficiency pages 1-3).

Molecular defect: ADSL catalyzes two non-sequential steps in de novo purine synthesis; in a 2023 paper’s abstract, “Adenylosuccinate lyase is required for de novo purine biosynthesis, acting twice in the pathway at non-sequential steps.” (PLOS Genetics, Sep 2023) (moro2023adenylosuccinatelyasedeficiency pages 1-2).

2.2 Risk factors

• Genetic: autosomal recessive inheritance; consanguinity can increase risk (e.g., homozygous variants reported in consanguineous families) (donti2016diagnosisofadenylosuccinate pages 3-4).
• Environmental: no established environmental risk factors were identified in the retrieved evidence; disease is primarily Mendelian (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, camici2023inbornerrorsof pages 9-11).

2.3 Protective factors / gene–environment interactions

No validated protective alleles or gene–environment interactions were identified in the retrieved evidence. Supportive factors may include early diagnosis and optimized symptomatic management (e.g., seizure control), but these are not “protective factors” in a causal sense (cutillo2024electroclinicalfeaturesand pages 14-15).

3. Phenotypes

3.1 Core phenotype spectrum and subtypes

A foundational review describes three clinical groupings and gives hallmark neonatal and pediatric presentations, including: “The fatal neonatal form has onset from birth… respiratory failure, and intractable seizures… early death within the first weeks of life.” and later forms with severe neurodevelopmental features. (jurecka2015adenylosuccinatelyasedeficiency pages 1-3)

A 2024 long-term cohort + literature appraisal provides a quantitative view of the spectrum (n=88 total, including 7 new and 81 literature cases): - Type I: 58% (51/88) - Type II: 28% (25/88) - Neonatal: 14% (12/88) (cutillo2024electroclinicalfeaturesand pages 1-2)

3.2 Epilepsy and electroclinical features (2024 update)

Epilepsy is common and often severe; the 2024 appraisal reports: “Epilepsy is present in 81.8% of the patients, with polymorphic and often intractable seizures.” (Epilepsia Open, Nov 2024) (cutillo2024electroclinicalfeaturesand pages 1-2).

The same paper summarizes typical EEG evolution: “EEG features seem to display common patterns and developmental trajectories: (i) poor general back-ground organization with theta-delta activity; (ii) hypsarrhythmia with spasms, usually adrenocorticotropic hormone-responsive; (iii) generalized epileptic discharges with frontal or frontal temporal predominance; and (iv) epileptic discharge activation in sleep with an altered sleep structure.” (cutillo2024electroclinicalfeaturesand pages 1-2).

3.3 Neurodevelopmental and neuromuscular phenotypes

A 2023 mechanistic/model-organism paper summarizes human features and emphasizes neuromuscular and neurobehavioral dysfunction; its abstract begins: “Adenylosuccinate lyase deficiency is an ultrarare congenital metabolic disorder associated with muscle weakness and neurobehavioral dysfunction.” (PLOS Genetics, Sep 2023) (moro2023adenylosuccinatelyasedeficiency pages 1-2).

Commonly described clinical features across reviews/cohorts include: - Developmental delay/intellectual disability; severe psychomotor retardation (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, donti2016diagnosisofadenylosuccinate pages 1-2) - Hypotonia; ataxia; dystonia (reported in clinical cohorts) (cutillo2024electroclinicalfeaturesand pages 2-4) - Autistic features/contact disturbances (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, camici2023inbornerrorsof pages 9-11) - Progressive cerebral/cerebellar atrophy and white matter changes on MRI in more severe phenotypes (cutillo2024electroclinicalfeaturesand pages 1-2, cutillo2024electroclinicalfeaturesand pages 2-4)

3.4 Suggested HPO terms (non-exhaustive; to be validated per case)

Based on phenotypes described in the cited literature (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, cutillo2024electroclinicalfeaturesand pages 1-2, cutillo2024electroclinicalfeaturesand pages 2-4): - Seizures (HP:0001250) - Epileptic spasms / Infantile spasms (HP:0012469) - Hypsarrhythmia (HP:0012465) - Global developmental delay (HP:0001263) - Intellectual disability (HP:0001249) - Hypotonia (HP:0001252) - Microcephaly (HP:0000252) - Autism (HP:0000717) / Autistic features - Ataxia (HP:0001251) - Dystonia (HP:0001332) - Cerebral atrophy (HP:0002059) - Cerebellar atrophy (HP:0001272)

3.5 Quality of life impact

No disease-specific QoL instruments were identified in the retrieved texts; however, long-term follow-up cases include severe disability (e.g., chronic refractory epilepsy, progressive neurodisability) implying major functional dependence (cutillo2024electroclinicalfeaturesand pages 2-4, cutillo2024electroclinicalfeaturesand pages 14-15).

4. Genetic / molecular information

4.1 Causal gene

• Gene: ADSL (adenylosuccinate lyase) (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, shi2025thediagnosisand pages 1-3)
• Inheritance: autosomal recessive (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, donti2016diagnosisofadenylosuccinate pages 1-2)

4.2 Variant spectrum and genotype–phenotype

The 2015 review notes: “Over 50 ADSL mutations have been identified” and the disorder is genetically heterogeneous (many private variants; frequent compound heterozygosity) (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, jurecka2015adenylosuccinatelyasedeficiency pages 4-6).

The 2024 appraisal reports the most frequently observed variants in compiled cases: “p.R426H homozygous (19 patients), p.Y114H in compound heterozygo-sity (13 patients), and p.D430N homozygous (6 patients).” (cutillo2024electroclinicalfeaturesand pages 1-2).

Genotype–phenotype relationships remain incomplete, but severity is suggested to track residual enzyme activity and certain variants are enriched in severe neonatal/type I phenotypes (cutillo2024electroclinicalfeaturesand pages 14-15).

4.3 Population data / carrier frequencies

From a 2016 diagnostic study referencing ExAC for ADSL p.Arg426His: - p.Arg426His is reported as the most common ADSL variant in ExAC, present on 31 chromosomes heterozygously, with allelic frequency 0.000255 and estimated carrier frequency ~1/2000; most carriers were non-Finnish European (28/31). (Molecular Genetics and Metabolism Reports, Sep 2016) (donti2016diagnosisofadenylosuccinate pages 3-4).

A 2015 review provided a broader, older estimate: an “estimated carrier (heterozygote) probability for a pathogenic ADSL allele of about 1:10,000.” (jurecka2015adenylosuccinatelyasedeficiency pages 4-6). Differences likely reflect method/variant set and database updates; current carrier frequency should be re-estimated using contemporary gnomAD with careful pathogenicity filtering.

4.4 Functional consequences

Evidence across reviews and model-organism work supports a dual mechanism: - Toxic substrate accumulation (SAICAR/SAICAr and related succinylpurines) - Reduced purine biosynthetic flux and impaired purine homeostasis

The C. elegans neurobehavioral work explicitly argues that altered behavior likely arises from accumulated substrate toxicity rather than only purine shortage (moro2023adenylosuccinatelyasedeficiency pages 1-2, moro2023adenylosuccinatelyasedeficiency pages 9-11).

5. Environmental information

No specific toxins, lifestyle factors, or infectious triggers were identified in the retrieved evidence. The disorder is primarily genetic, and management focuses on symptomatic care and experimental metabolic interventions (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, camici2023inbornerrorsof pages 9-11).

6. Mechanism / pathophysiology

6.1 Pathway context

ADSL is required for de novo purine biosynthesis and acts twice at non-sequential steps (moro2023adenylosuccinatelyasedeficiency pages 1-2). A clinical review focused on epilepsy reiterates the enzymatic steps and toxic metabolite hypothesis in ADSL deficiency (shi2025thediagnosisand pages 1-3).

Biochemical hallmark: accumulation of SAICAr and S‑Ado in extracellular fluids (urine, CSF, plasma) (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, jurecka2015adenylosuccinatelyasedeficiency pages 8-9).

6.2 Proposed causal chain (integrated)

1) Biallelic ADSL variants → reduced ADSL activity (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, donti2016diagnosisofadenylosuccinate pages 1-2) 2) Block at ADSL-catalyzed steps → accumulation of phosphorylated substrates → extracellular dephosphorylated succinylpurines (SAICAr, S‑Ado) (jurecka2015adenylosuccinatelyasedeficiency pages 8-9, jurecka2015adenylosuccinatelyasedeficiency pages 1-3) 3) Neurodevelopmental dysfunction via a combination of toxic metabolite effects and purine imbalance; model-organism data show broader metabolic perturbations (e.g., neurotransmitter signaling disruption) downstream of purine pathway disruption (moro2023adenylosuccinatelyasedeficiency pages 1-2, moro2023adenylosuccinatelyasedeficiency pages 9-11) 4) Clinical manifestations: developmental delay/intellectual disability, hypotonia/ataxia, epilepsy with characteristic EEG patterns, and progressive neuroimaging abnormalities in severe phenotypes (cutillo2024electroclinicalfeaturesand pages 1-2, cutillo2024electroclinicalfeaturesand pages 2-4)

6.3 Mechanistic advances (2023–2024)

Neurobehavioral mechanism in C. elegans (2023): substrate accumulation due to adsl-1 deficiency perturbs tyrosine metabolism and tyramine signaling; behavioral phenotypes are rescued by tyramine supplementation and involve TYRA-2 receptor signaling (moro2023adenylosuccinatelyasedeficiency pages 1-2, moro2023adenylosuccinatelyasedeficiency pages 11-13, moro2023adenylosuccinatelyasedeficiency pages 9-11).

Separability of phenotypic etiologies (2023): a C. elegans model suggests neuromuscular defects associate with intermediate accumulation while reproductive defects are rescued by purine supplementation—supporting the concept that multiple downstream mechanisms contribute to phenotype heterogeneity (fenton2023acaenorhabditiselegans pages 1-3, fenton2023acaenorhabditiselegans pages 8-9).

6.4 Suggested ontology terms

GO Biological Process (suggested): - de novo IMP biosynthetic process (purine biosynthesis) - AMP biosynthetic process - purine nucleotide metabolic process

GO Molecular Function (suggested): - adenylosuccinate lyase activity

Cell types (CL; suggested, based on neurologic phenotype/EEG patterns): - neurons (CL:0000540) - astrocytes (CL:0000127) - oligodendrocytes (CL:0000128)

Anatomy (UBERON; suggested): - brain (UBERON:0000955) - cerebellum (UBERON:0002037) - cerebral cortex/frontal lobe (UBERON mapping; frontal predominance described on imaging) (cutillo2024electroclinicalfeaturesand pages 1-2)

7. Anatomical structures affected

Human cohorts and reviews emphasize CNS involvement with imaging showing cerebral/cerebellar atrophy and white matter abnormalities in many patients (cutillo2024electroclinicalfeaturesand pages 1-2, cutillo2024electroclinicalfeaturesand pages 2-4). Neuromuscular involvement (hypotonia, muscle weakness) is frequently noted (moro2023adenylosuccinatelyasedeficiency pages 1-2).

8. Temporal development

• Onset ranges from congenital/neonatal (fatal neonatal encephalopathy) to onset in the first years of life for type I and later onset in milder type II forms (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, cutillo2024electroclinicalfeaturesand pages 1-2).
• Progression varies: rapidly progressive neonatal/type I vs slower courses in type II; long-term follow-up documents persistent epilepsy and progressive neurodisability in some patients over decades (cutillo2024electroclinicalfeaturesand pages 2-4, cutillo2024electroclinicalfeaturesand pages 14-15).

9. Inheritance and population

• Inheritance: autosomal recessive (jurecka2015adenylosuccinatelyasedeficiency pages 1-3, donti2016diagnosisofadenylosuccinate pages 1-2)
• Epidemiology: incidence/prevalence remain uncertain; historical reviews noted “More than 80 individuals” identified by 2015 (jurecka2015adenylosuccinatelyasedeficiency pages 1-3), while the 2024 appraisal aggregated 88 patients (81 literature + 7 new) (cutillo2024electroclinicalfeaturesand pages 1-2).
• Variant enrichment/founder effects: p.Arg426His is repeatedly the most common variant in patient cohorts and appears enriched in Europeans; ExAC-based estimates are provided above (donti2016diagnosisofadenylosuccinate pages 3-4, jurecka2015adenylosuccinatelyasedeficiency pages 4-6).

10. Diagnostics

10.1 Biochemical testing (core real-world implementation)

The most established diagnostic hallmark is detecting elevated succinylpurines. The review states: “Diagnosis is facilitated by demonstration of SAICAr and S-Ado in extracellular fluids such as plasma, cerebrospinal fluid…” (jurecka2015adenylosuccinatelyasedeficiency pages 1-3).

Methods described include HPLC-UV/HPLC-MS and high-throughput HPLC-ESI-MS/MS approaches; urine is commonly used, with CSF and plasma also reported (jurecka2015adenylosuccinatelyasedeficiency pages 8-9).

10.2 Metabolomics-based diagnosis

A 2016 study demonstrated untargeted plasma metabolomics as an alternative route to diagnosis and phenotype expansion, describing ADSL deficiency as OMIM 103050 and emphasizing SAICAr/S‑Ado accumulation as the biochemical hallmark typically detected in urine (donti2016diagnosisofadenylosuccinate pages 1-2).

10.3 Genetic testing

Diagnostic confirmation includes genomic sequencing (single-gene testing, panels, WES/WGS) and sometimes functional enzyme assessment; WES is emphasized as valuable for atypical/mild phenotypes (macchiaiolo2017amildform pages 7-7, jurecka2015adenylosuccinatelyasedeficiency pages 8-9).

10.4 Differential diagnosis

Not comprehensively extracted from the retrieved texts. In practice, differential diagnosis includes other inborn errors of metabolism presenting with developmental epileptic encephalopathy; nucleotide metabolism epilepsy reviews discuss ADSL deficiency among other nucleic acid/nucleotide disorders (shi2025thediagnosisand pages 1-3).

10.5 Newborn screening

No evidence in retrieved texts confirms routine newborn screening implementation for ADSL deficiency; given the need for specialized metabolite testing and uncertain treatability, ADSL deficiency is not established as a standard NBS target in the retrieved evidence.

11. Outcomes / prognosis

Outcomes depend strongly on subtype. Neonatal forms can be fatal in weeks (jurecka2015adenylosuccinatelyasedeficiency pages 1-3). Long-term follow-up (10–34 years) demonstrates survival into adulthood for some patients, but with severe disability and often drug-resistant epilepsy in type I and neonatal phenotypes (cutillo2024electroclinicalfeaturesand pages 2-4, cutillo2024electroclinicalfeaturesand pages 14-15).

12. Treatment

12.1 Current standard-of-care (real-world)

There is no proven disease-modifying therapy; reviews emphasize symptomatic management. The 2015 review states: “To date there is no specific and effective therapy for ADSL deficiency.” (jurecka2015adenylosuccinatelyasedeficiency pages 1-3).

Supportive/standard management includes: - Anti-seizure medications (ASM); some benefit in milder cases (cutillo2024electroclinicalfeaturesand pages 14-15) - Developmental therapies and supportive care (implied; not detailed in retrieved texts)

12.2 Allopurinol (repurposing; clinical trial implementation)

ClinicalTrials.gov NCT03776656 (Phase 2, single-group, n=8, completed) evaluated oral allopurinol for 12 months. Key details: - Primary endpoint: Vineland II adaptive behavior composite score at 12 months (NCT03776656 chunk 1) - Biochemical endpoints: serial urinary and plasma SAICAr and S‑Ado (NCT03776656 chunk 2, NCT03776656 chunk 1) - Trial rationale notes the hypothesis that allopurinol reduces production of toxic SAICAr, and the protocol states the hypothesis “was validated in 3 minor patients with biological and clinical improvement” (NCT03776656 chunk 1).

The trial record also cites a linked publication (not retrievable here) titled: “Allopurinol Treatment Improves Cognitive Skills, Adaptive Behavior, and Biochemical Markers in Young Patients With Adenylosuccinate Lyase Deficiency” (PMID listed in the record) (NCT03776656 chunk 2). Interpretation should be cautious until full peer-reviewed results are examined.

12.3 Other attempted metabolic interventions (limited/experimental)

Across reviews and cohort appraisal, reported attempts include: - Ketogenic diet trials with transient effects (camici2023inbornerrorsof pages 9-11) - D-ribose (inconsistent/limited evidence) (camici2023inbornerrorsof pages 9-11, cutillo2024electroclinicalfeaturesand pages 14-15) - S-adenosyl-L-methionine (limited success) (cutillo2024electroclinicalfeaturesand pages 14-15) - Uridine (mentioned among attempted therapies in epilepsy-focused reviews) (shi2025thediagnosisand pages 1-3)

12.4 Suggested MAXO terms (examples)

• Allopurinol therapy (MAXO term to be mapped)
• Anticonvulsant therapy
• Ketogenic diet therapy
• Genetic counseling

13. Prevention

Primary prevention is not applicable beyond reproductive options because this is a Mendelian disorder. - Carrier screening / cascade testing in families; prenatal diagnosis is described as limited to families with an affected child and relies on mutation testing (jurecka2015adenylosuccinatelyasedeficiency pages 8-9). - Secondary prevention: earlier diagnosis to optimize seizure control and supportive interventions (jurecka2015adenylosuccinatelyasedeficiency pages 8-9).

14. Other species / natural disease

No naturally occurring veterinary syndrome was identified in the retrieved evidence.

15. Model organisms

15.1 C. elegans (2023): mechanistic and translational utility

Two 2023 studies establish and leverage a C. elegans adsl-1 model: - Neuromuscular and reproductive phenotypes with separable etiologies; some mobility defects reversible; fertility rescued by purine supplementation (fenton2023acaenorhabditiselegans pages 1-3, fenton2023acaenorhabditiselegans pages 8-9) - Neurobehavioral phenotypes driven by disrupted tyramine signaling downstream of adsl-1 deficiency; tyramine supplementation rescues gustatory plasticity phenotype (moro2023adenylosuccinatelyasedeficiency pages 1-2, moro2023adenylosuccinatelyasedeficiency pages 11-13, moro2023adenylosuccinatelyasedeficiency pages 9-11)

Applications: pathway dissection (substrate toxicity vs purine deficiency), screening candidate interventions (e.g., pathway inhibitors or supplementation), and probing neurobehavioral mechanisms (fenton2023acaenorhabditiselegans pages 8-9, moro2023adenylosuccinatelyasedeficiency pages 9-11).

Key recent developments (2023–2024) — highlights

• Clinical natural history/electroclinical patterns (2024): consolidated cohort of 88 patients, epilepsy prevalence 81.8%, and described EEG trajectories and imaging patterns (cutillo2024electroclinicalfeaturesand pages 1-2).
• Mechanistic expansion (2023): evidence that ADSL deficiency can perturb neurotransmitter pathways (tyramine signaling) in vivo in a genetic model, supporting wider metabolic effects beyond purine synthesis itself (moro2023adenylosuccinatelyasedeficiency pages 1-2).

Limitations of this report (evidence gaps)

• Orphanet (ORPHA), ICD-10/ICD-11, and definitive MeSH UID were not directly extractable from the retrieved full text and should be added via dedicated database queries.
• The linked allopurinol results publication cited by ClinicalTrials.gov could not be retrieved in full text in this run; conclusions about efficacy should be treated as provisional until peer-reviewed results are reviewed (NCT03776656 chunk 2).

References

1. (jurecka2015adenylosuccinatelyasedeficiency pages 1-3): Agnieszka Jurecka, Marie Zikanova, Stanislav Kmoch, and Anna Tylki‐Szymańska. Adenylosuccinate lyase deficiency. Journal of Inherited Metabolic Disease, 38:231-242, Aug 2015. URL: https://doi.org/10.1007/s10545-014-9755-y, doi:10.1007/s10545-014-9755-y. This article has 158 citations and is from a peer-reviewed journal.

2. (donti2016diagnosisofadenylosuccinate pages 1-2): Taraka R. Donti, Gerarda Cappuccio, Leroy Hubert, Juanita Neira, Paldeep S. Atwal, Marcus J. Miller, Aaron L. Cardon, V. Reid Sutton, Brenda E. Porter, Fiona M. Baumer, Michael F. Wangler, Qin Sun, Lisa T. Emrick, and Sarah H. Elsea. Diagnosis of adenylosuccinate lyase deficiency by metabolomic profiling in plasma reveals a phenotypic spectrum. Molecular Genetics and Metabolism Reports, 8:61-66, Sep 2016. URL: https://doi.org/10.1016/j.ymgmr.2016.07.007, doi:10.1016/j.ymgmr.2016.07.007. This article has 66 citations.

3. (cutillo2024electroclinicalfeaturesand pages 1-2): Gianni Cutillo, Silvia Masnada, Gaetan Lesca, Dorothée Ville, Patrizia Accorsi, Lucio Giordano, Anna Pichiecchio, Marialuisa Valente, Paola Borrelli, Ottavia Eleonora Ferraro, and Pierangelo Veggiotti. Electroclinical features and phenotypic differences in adenylosuccinate lyase deficiency: long‐term follow‐up of seven patients from four families and appraisal of the literature. Epilepsia Open, 9:106-121, Nov 2024. URL: https://doi.org/10.1002/epi4.12837, doi:10.1002/epi4.12837. This article has 5 citations and is from a peer-reviewed journal.

4. (moro2023adenylosuccinatelyasedeficiency pages 1-2): Corinna A. Moro, Sabrina A. Sony, Latisha P. Franklin, Shirley Dong, Mia M. Peifer, Kathryn E. Wittig, and Wendy Hanna-Rose. Adenylosuccinate lyase deficiency affects neurobehavior via perturbations to tyramine signaling in caenorhabditis elegans. PLOS Genetics, 19:e1010974, Sep 2023. URL: https://doi.org/10.1371/journal.pgen.1010974, doi:10.1371/journal.pgen.1010974. This article has 8 citations and is from a domain leading peer-reviewed journal.

5. (NCT03776656 chunk 2): Evaluation of a Treatment With Allopurinol in Adenylosuccinate Lyase Deficiency. Assistance Publique - Hôpitaux de Paris. 2019. ClinicalTrials.gov Identifier: NCT03776656

6. (NCT03776656 chunk 1): Evaluation of a Treatment With Allopurinol in Adenylosuccinate Lyase Deficiency. Assistance Publique - Hôpitaux de Paris. 2019. ClinicalTrials.gov Identifier: NCT03776656

7. (fenton2023acaenorhabditiselegans pages 1-3): Adam R. Fenton, Haley N. Janowitz, Latisha P. Franklin, Riley G. Young, Corinna A. Moro, Michael V. DeGennaro, Melanie R. McReynolds, Wenqing Wang, and Wendy Hanna-Rose. A caenorhabditis elegans model of adenylosuccinate lyase deficiency reveals neuromuscular and reproductive phenotypes of distinct etiology. Molecular Genetics and Metabolism, 140:107686, Nov 2023. URL: https://doi.org/10.1016/j.ymgme.2023.107686, doi:10.1016/j.ymgme.2023.107686. This article has 5 citations and is from a peer-reviewed journal.

8. (fenton2023acaenorhabditiselegans pages 15-16): Adam R. Fenton, Haley N. Janowitz, Latisha P. Franklin, Riley G. Young, Corinna A. Moro, Michael V. DeGennaro, Melanie R. McReynolds, Wenqing Wang, and Wendy Hanna-Rose. A caenorhabditis elegans model of adenylosuccinate lyase deficiency reveals neuromuscular and reproductive phenotypes of distinct etiology. Molecular Genetics and Metabolism, 140:107686, Nov 2023. URL: https://doi.org/10.1016/j.ymgme.2023.107686, doi:10.1016/j.ymgme.2023.107686. This article has 5 citations and is from a peer-reviewed journal.

9. (camici2023inbornerrorsof pages 9-11): Marcella Camici, Mercedes Garcia-Gil, Simone Allegrini, Rossana Pesi, Giulia Bernardini, Vanna Micheli, and Maria Grazia Tozzi. Inborn errors of purine salvage and catabolism. Metabolites, 13:787, Jun 2023. URL: https://doi.org/10.3390/metabo13070787, doi:10.3390/metabo13070787. This article has 22 citations.

10. (cutillo2024electroclinicalfeaturesand pages 2-4): Gianni Cutillo, Silvia Masnada, Gaetan Lesca, Dorothée Ville, Patrizia Accorsi, Lucio Giordano, Anna Pichiecchio, Marialuisa Valente, Paola Borrelli, Ottavia Eleonora Ferraro, and Pierangelo Veggiotti. Electroclinical features and phenotypic differences in adenylosuccinate lyase deficiency: long‐term follow‐up of seven patients from four families and appraisal of the literature. Epilepsia Open, 9:106-121, Nov 2024. URL: https://doi.org/10.1002/epi4.12837, doi:10.1002/epi4.12837. This article has 5 citations and is from a peer-reviewed journal.

11. (donti2016diagnosisofadenylosuccinate pages 3-4): Taraka R. Donti, Gerarda Cappuccio, Leroy Hubert, Juanita Neira, Paldeep S. Atwal, Marcus J. Miller, Aaron L. Cardon, V. Reid Sutton, Brenda E. Porter, Fiona M. Baumer, Michael F. Wangler, Qin Sun, Lisa T. Emrick, and Sarah H. Elsea. Diagnosis of adenylosuccinate lyase deficiency by metabolomic profiling in plasma reveals a phenotypic spectrum. Molecular Genetics and Metabolism Reports, 8:61-66, Sep 2016. URL: https://doi.org/10.1016/j.ymgmr.2016.07.007, doi:10.1016/j.ymgmr.2016.07.007. This article has 66 citations.

12. (cutillo2024electroclinicalfeaturesand pages 14-15): Gianni Cutillo, Silvia Masnada, Gaetan Lesca, Dorothée Ville, Patrizia Accorsi, Lucio Giordano, Anna Pichiecchio, Marialuisa Valente, Paola Borrelli, Ottavia Eleonora Ferraro, and Pierangelo Veggiotti. Electroclinical features and phenotypic differences in adenylosuccinate lyase deficiency: long‐term follow‐up of seven patients from four families and appraisal of the literature. Epilepsia Open, 9:106-121, Nov 2024. URL: https://doi.org/10.1002/epi4.12837, doi:10.1002/epi4.12837. This article has 5 citations and is from a peer-reviewed journal.

13. (shi2025thediagnosisand pages 1-3): Yuqing Shi, Zihan Wei, Yan Feng, Ya-Jing Gan, Guo-Yan Li, and Yanchun Deng. The diagnosis and treatment of disorders of nucleic acid/nucleotide metabolism associated with epilepsy. Acta Epileptologica, Apr 2025. URL: https://doi.org/10.1186/s42494-025-00201-x, doi:10.1186/s42494-025-00201-x. This article has 3 citations.

14. (jurecka2015adenylosuccinatelyasedeficiency pages 4-6): Agnieszka Jurecka, Marie Zikanova, Stanislav Kmoch, and Anna Tylki‐Szymańska. Adenylosuccinate lyase deficiency. Journal of Inherited Metabolic Disease, 38:231-242, Aug 2015. URL: https://doi.org/10.1007/s10545-014-9755-y, doi:10.1007/s10545-014-9755-y. This article has 158 citations and is from a peer-reviewed journal.

15. (moro2023adenylosuccinatelyasedeficiency pages 9-11): Corinna A. Moro, Sabrina A. Sony, Latisha P. Franklin, Shirley Dong, Mia M. Peifer, Kathryn E. Wittig, and Wendy Hanna-Rose. Adenylosuccinate lyase deficiency affects neurobehavior via perturbations to tyramine signaling in caenorhabditis elegans. PLOS Genetics, 19:e1010974, Sep 2023. URL: https://doi.org/10.1371/journal.pgen.1010974, doi:10.1371/journal.pgen.1010974. This article has 8 citations and is from a domain leading peer-reviewed journal.

16. (jurecka2015adenylosuccinatelyasedeficiency pages 8-9): Agnieszka Jurecka, Marie Zikanova, Stanislav Kmoch, and Anna Tylki‐Szymańska. Adenylosuccinate lyase deficiency. Journal of Inherited Metabolic Disease, 38:231-242, Aug 2015. URL: https://doi.org/10.1007/s10545-014-9755-y, doi:10.1007/s10545-014-9755-y. This article has 158 citations and is from a peer-reviewed journal.

17. (moro2023adenylosuccinatelyasedeficiency pages 11-13): Corinna A. Moro, Sabrina A. Sony, Latisha P. Franklin, Shirley Dong, Mia M. Peifer, Kathryn E. Wittig, and Wendy Hanna-Rose. Adenylosuccinate lyase deficiency affects neurobehavior via perturbations to tyramine signaling in caenorhabditis elegans. PLOS Genetics, 19:e1010974, Sep 2023. URL: https://doi.org/10.1371/journal.pgen.1010974, doi:10.1371/journal.pgen.1010974. This article has 8 citations and is from a domain leading peer-reviewed journal.

18. (fenton2023acaenorhabditiselegans pages 8-9): Adam R. Fenton, Haley N. Janowitz, Latisha P. Franklin, Riley G. Young, Corinna A. Moro, Michael V. DeGennaro, Melanie R. McReynolds, Wenqing Wang, and Wendy Hanna-Rose. A caenorhabditis elegans model of adenylosuccinate lyase deficiency reveals neuromuscular and reproductive phenotypes of distinct etiology. Molecular Genetics and Metabolism, 140:107686, Nov 2023. URL: https://doi.org/10.1016/j.ymgme.2023.107686, doi:10.1016/j.ymgme.2023.107686. This article has 5 citations and is from a peer-reviewed journal.

19. (macchiaiolo2017amildform pages 7-7): Marina Macchiaiolo, Sabina Barresi, Francesco Cecconi, Ginevra Zanni, Marcello Niceta, Emanuele Bellacchio, Giacomo Lazzarino, Angela Maria Amorini, Enrico Silvio Bertini, Salvatore Rizza, Benedetta Contardi, Marco Tartaglia, and Andrea Bartuli. A mild form of adenylosuccinate lyase deficiency in absence of typical brain mri features diagnosed by whole exome sequencing. Italian Journal of Pediatrics, Aug 2017. URL: https://doi.org/10.1186/s13052-017-0383-7, doi:10.1186/s13052-017-0383-7. This article has 16 citations and is from a peer-reviewed journal.

1. Disease Information

Overview

Adenylosuccinate lyase deficiency (ADSLD) is an ultra-rare autosomal recessive neurometabolic disorder first identified in 1984 by Jaeken and Van den Berghe as the first inborn defect of purine biosynthesis. The disease results from loss-of-function mutations in the ADSL gene, leading to impaired de novo purine synthesis and purine nucleotide recycling. ADSLD is characterized by "severe neurological impairment, with an estimated global prevalence of approximately 0.00125 cases per 100,000 individuals" (PMID: 40896413).

Key Identifiers

Synonyms and Alternative Names

• Adenylosuccinate lyase deficiency (ADSLD)
• ADSL deficiency
• Adenylosuccinase deficiency
• Succinylpurinemic autism
• Adenylosuccinate lyase deficiency disorder (ADSLDD)

Information Sources

Information is derived primarily from aggregated disease-level resources (OMIM, Orphanet, GeneReviews) supplemented by individual case reports and small case series in the published literature, as well as patient registries such as the "Our Journey with ADSL Deficiency Association." As an ultra-rare disorder, much of the clinical knowledge comes from case reports, small case series, and literature reviews of collectively ~100 identified patients worldwide.

2. Etiology

Disease Causal Factors

Primary Cause: Genetic

ADSLD is caused exclusively by homozygous or compound heterozygous loss-of-function mutations in the ADSL gene. The enzyme ADSL is a homotetrameric protein belonging to the fumarase/aspartase superfamily that catalyzes two reactions in purine metabolism:

1. De novo IMP synthesis (step 8 of 10): Conversion of SAICAR to AICAR + fumarate
2. Purine nucleotide recycling / AMP synthesis: Conversion of adenylosuccinate (S-AMP) to AMP + fumarate

As described by Jurecka et al., "Adenylosuccinate lyase (ADSL) deficiency is a defect of purine metabolism affecting purinosome assembly and reducing metabolite fluxes through purine de novo synthesis and purine nucleotide recycling pathways" (PMID: 25112391).

Deficiency leads to: - Accumulation of dephosphorylated substrates: SAICAr and S-Ado in body fluids - Reduced purine nucleotide pools (AMP, GMP, and their derivatives) - Impaired purinosome assembly (the multi-enzyme complex for de novo purine synthesis) (PMID: 22180458)

Mechanistic factors: - Toxic accumulation of SAICAr (particularly neurotoxic) (PMID: 40896413) - Purine nucleotide depletion impairing energy metabolism - Secondary mitochondrial dysfunction (PMID: 40914938) - Complement-mediated neuroinflammation (PMID: 40896413)

Risk Factors

Genetic Risk Factors: - Biallelic pathogenic variants in ADSL (causal, required for disease) - More than 70 distinct pathogenic variants have been reported, predominantly missense mutations (PMID: 25112391) - Most frequent pathogenic variants: p.R426H (homozygous in 19 patients), p.Y114H (compound heterozygous in 13 patients), p.D430N (homozygous in 6 patients) (PMID: 37842880) - Consanguinity is a risk factor, as the disease follows autosomal recessive inheritance

Environmental Risk Factors: - No specific environmental risk factors have been identified for this Mendelian disorder - The disease is entirely genetically determined - Intercurrent illnesses (febrile episodes) may exacerbate seizures - D-ribose supplementation withdrawal was associated with acute neurological deterioration in one patient (PMID: 21903433)

Protective Factors

Genetic Protective Factors: - Higher residual ADSL enzyme activity is associated with milder disease (type II vs type I) (PMID: 20127976) - Greater structural stability of mutant ADSL protein complexes correlates with milder phenotype - Some compound heterozygous combinations may result in milder disease through intersubunit complementation in the homotetramer

Environmental Protective Factors: - No specific environmental protective factors have been identified - Ketogenic diet has shown some benefit for seizure control in individual cases (PMID: 23504561)

Gene-Environment Interactions

No specific gene-environment interactions have been documented for ADSLD. As a Mendelian recessive disorder, the disease phenotype is primarily determined by the nature and combination of ADSL pathogenic variants and their effect on residual enzyme activity. However, bacterial urinary tract infections can cause deribosylation of urinary biomarkers, complicating diagnosis (PMID: 24183879).

3. Phenotypes

Clinical Phenotypic Spectrum

ADSLD presents as a phenotypic continuum classified into three major categories (PMID: 25112391; PMID: 37842880; PMID: 40896413):

Fatal Neonatal Form (~14% of cases)

• Onset: Birth to first days of life
• Severity: Lethal
• Features: Neonatal encephalopathy, absence of spontaneous movement, respiratory failure, intractable seizures, death within weeks
• HPO terms: Neonatal encephalopathy (HP:0012736), Respiratory failure (HP:0002878), Neonatal onset (HP:0003623)
• S-Ado/SAICAr ratio: Very low (< 1)

Type I -- Severe Infantile Form (~58% of cases)

• Onset: First months of life (median 0.63 years)
• Severity: Severe
• Features: Severe psychomotor retardation, early-onset seizures, microcephaly, autistic features, hypotonia progressing to spasticity
• HPO terms: Severe global developmental delay (HP:0011344), Epileptic encephalopathy (HP:0200134), Microcephaly (HP:0000252), Autistic behavior (HP:0000729), Muscular hypotonia (HP:0001252)
• S-Ado/SAICAr ratio: Low (< 2)

Type II -- Moderate/Mild Form (~28% of cases)

• Onset: First months to years of life
• Severity: Mild to moderate
• Features: Mild to moderate psychomotor retardation, later-onset seizures, transient contact disturbances, behavioral abnormalities
• HPO terms: Global developmental delay (HP:0001263), Seizures (HP:0001250), Intellectual disability (HP:0001249)
• S-Ado/SAICAr ratio: Higher (> 2)

Comprehensive Phenotype Catalog

Strikingly, as reported by Brun et al., "In the majority (89.2%), disease onset was within the first year of life. Epilepsy is present in 81.8% of the patients, with polymorphic and often intractable seizures" (PMID: 37842880).

EEG Features (PMID: 37842880)

• Poor general background organization with theta-delta activity
• Hypsarrhythmia with infantile spasms (common developmental trajectory)
• Multifocal epileptiform discharges

Behavioral Phenotype

An important and sometimes misleading behavioral phenotype includes features mimicking Angelman syndrome: "excessive laughter, a very happy disposition, hyperactivity, a short attention span, the mouthing of objects, tantrums and stereotyped movements" (PMID: 18830228). This overlap can lead to significant diagnostic delays.

ADSLD has been listed among "several genetic diseases consistently associated with autism," including fragile X, tuberous sclerosis, Angelman syndrome, and others (PMID: 15796126).

Quality of Life Impact

• Severe cognitive impairment affects daily functioning in most patients
• Drug-resistant epilepsy significantly impacts quality of life
• Most patients require full-time care
• Communication deficits (speech delay/absence) limit social participation
• Motor impairments limit mobility and independence
• Type II patients may attend special education and achieve some independence (PMID: 23504561)
• No formal EQ-5D or SF-36 assessments have been published for ADSLD

Brain MRI Findings

Brain MRI abnormalities are characteristic and include impaired white matter myelination, global supra- and infratentorial white matter loss, widening of lateral ventricles, cerebral and cerebellar atrophy, and white matter hyperintense signal on T2-weighted sequences. As Jurecka et al. described: "Head MRI showed impaired white matter myelination with various degrees of global supra- and infratentorial white matter loss" (PMID: 21625931). Notably, MRI may be normal in some mild cases (PMID: 28768552).

4. Genetic/Molecular Information

Causal Gene

ADSL (Adenylosuccinate Lyase) - HGNC ID: HGNC:291 - NCBI Gene ID: 158 - OMIM Gene: 608222 - OMIM Phenotype: #103050 - Ensembl: ENSG00000239900 - Chromosomal location: 22q13.1 - Gene structure: 13 exons spanning ~23 kb (PMID: 10888601) - Protein: 484 amino acids, functions as a homotetramer - EC number: 4.3.2.2 - Protein family: Fumarase/aspartase superfamily - UniProt*: P30566

Pathogenic Variants

Over 70 distinct pathogenic variants have been reported. The vast majority are missense mutations, consistent with the requirement for some residual enzyme activity for survival. Complete loss of ADSL activity is likely embryonically lethal.

Most Common Variants:

Variant Classification and Functional Consequences: - Classification: Most identified variants are pathogenic or likely pathogenic per ACMG/AMP guidelines (ClinVar) - Origin: All germline - Types: Predominantly missense; rare nonsense (e.g., p.R190X) and splice-site mutations - Allele frequencies: Extremely rare in population databases (gnomAD); most variants are private or found in very few families - Functional consequence: Loss of function -- all pathogenic variants reduce ADSL enzyme activity to varying degrees - Genotype-phenotype correlation: "Phenotypic severity in ADSL deficiency is correlated with residual enzymatic activity and structural stability of the corresponding mutant ADSL complexes and does not seem to result from genotype-specific disproportional catalytic activities toward one of the enzyme substrates" (PMID: 20127976)

Alternative Splicing

An alternatively spliced isoform resulting from exon 12 skipping has been identified. The non-spliced form is approximately 10-fold more abundant, and only the unspliced ADSL is enzymatically active (PMID: 10888601).

Protein Structural Consequences

The P100A substitution "distorts the amino acid chain of domain I in the proximity of His-86, which behaves as general acid in the catalysis, and may expose Cys-98 and Cys-99 to oxidising agents" (PMID: 15571240). This model is consistent with the observation that the defective protein is strongly inhibited by 4-hydroxy-2-nonenal, an oxidative stress product.

Modifier Genes

No established modifier genes have been identified for ADSLD. However, genes involved in purine salvage pathways (e.g., HPRT1, APRT) could theoretically modify disease severity by affecting alternative purine supply.

Epigenetic Information

No specific epigenetic modifications have been directly associated with ADSLD pathogenesis. This represents a knowledge gap in the field.

Chromosomal Abnormalities

Not applicable. ADSLD is caused by point mutations (primarily missense) in the ADSL gene, not large-scale chromosomal abnormalities.

5. Environmental Information

Environmental Factors

ADSLD is a purely genetic disorder with no known environmental causes. There are no established environmental, infectious, or non-genetic causal factors.

Lifestyle Factors

• Diet: A ketogenic diet has been reported to improve seizure control in one patient with type II ADSLD: "Due to poor results in seizure control, the ketogenic diet was introduced at the age of 7 years, resulting in reduction of seizure frequency" (PMID: 23504561)
• D-ribose therapy: Attempted in one patient; withdrawal was associated with acute neurological deterioration, severe brain atrophy and demyelination on MRI (PMID: 21903433)
• Exercise, smoking, alcohol: Not specifically studied; not applicable given the typical pediatric onset

Infectious Agents

Not applicable as causative agents. However, urinary tract infections can interfere with diagnostic testing by causing bacterial deribosylation of the urinary biomarkers SAICAr and S-Ado (PMID: 24183879).

6. Mechanism / Pathophysiology

Molecular Pathways

The primary biochemical defect in ADSLD involves two critical pathways:

1. De novo purine synthesis pathway (KEGG: hsa00230): ADSL catalyzes step 8 of the 10-step conversion of PRPP to IMP, converting SAICAR to AICAR
2. Purine nucleotide recycling/interconversion (KEGG: hsa00230): ADSL converts adenylosuccinate (S-AMP) to AMP in the IMP-to-AMP conversion branch

GO terms: Purine nucleotide biosynthetic process (GO:0006164), Adenylosuccinate lyase activity (GO:0004018), 'de novo' IMP biosynthetic process (GO:0006189), AMP biosynthetic process (GO:0006167), SAICAR lyase activity (GO:0070626)

Causal Chain: From Genetic Defect to Clinical Disease

ADSL Gene Mutation (germline, biallelic)
       |
       v
Reduced ADSL Enzyme Activity & Protein Instability
       |
       +---> Impaired Purinosome Assembly (multi-enzyme complex disruption)
       |
       v
Two Concurrent Biochemical Consequences:
       |
       +---> 1. ACCUMULATION of toxic succinylpurines
       |         (SAICAr and S-Ado in body fluids)
       |              |
       |              +---> SAICAr neurotoxicity
       |              |     (promotes neuroinflammation)
       |              |
       |              +---> Complement pathway activation
       |              |     (alternative pathway)
       |              |
       |              +---> Blood-brain barrier disruption
       |              |
       |              +---> Progressive neurodegeneration
       |
       +---> 2. DEPLETION of purine nucleotides
 (reduced AMP/GMP/ATP production)
      |
      +---> Mitochondrial dysfunction
      |     (fragmentation, impaired respiration)
      |
      +---> ERK2/AKT signaling suppression
      |
      +---> Impaired energy metabolism
      |
      +---> Impaired DNA/RNA synthesis
      |
      v
    NEUROLOGICAL DAMAGE
    (seizures, developmental delay,
     white matter loss, brain atrophy)

Purinosome Assembly Disruption

A critical upstream mechanism is the disruption of purinosome assembly. Purinosomes are dynamic multi-enzyme complexes that channel substrates through the de novo purine synthesis pathway. Marie et al. demonstrated that "various mutations of ATIC and ADSL destabilize to various degrees of purinosome assembly and found that the ability to form purinosomes correlates with clinical phenotypes of individual ADSL patients" (PMID: 22180458). This finding establishes purinosome disruption as a proximal mechanistic step linking genotype to phenotype.

Secondary Mitochondrial Dysfunction

A major recent advance is the recognition of ADSLD as a secondary mitochondrial disease. As reported by Ast et al.: "ADSLd is associated with mitochondrial dysfunction, including increased fragmentation, impaired respiration, and reduced ATP production. The severity of mitochondrial impairment correlates with ADSLd pathology, especially in mitochondria-dependent tissues" (PMID: 40914938). Key features include:

• Increased mitochondrial fragmentation (disrupted fission/fusion dynamics)
• Impaired oxidative phosphorylation (reduced complex I-IV activity)
• Reduced ATP production (energy deficit in neurons and other high-demand tissues)
• Defects in mitochondrial transport (impaired axonal trafficking)
• ERK2 and AKT signaling suppression (growth/survival pathway impairment)

Overexpression of constitutively active ERK2 or supplementation with purine intermediates partially rescues the mitochondrial phenotype, demonstrating the causal link between purine depletion and mitochondrial dysfunction.

GO terms: Mitochondrial organization (GO:0007005), Oxidative phosphorylation (GO:0006119), Mitochondrial fission (GO:0000266), ATP metabolic process (GO:0046034), Aerobic respiration (GO:0009060)

Complement-Mediated Neuroinflammation

Emerging evidence implicates the alternative complement pathway as a key mediator of neurodegeneration. As described in a 2025 review: "We highlight emerging hypotheses implicating activation of the alternative complement pathway as a key driver of inflammation, blood-brain barrier disruption, and progressive neurodegeneration" (PMID: 40896413).

SAICAr, the more toxic of the two accumulated succinylpurines, appears to promote neuroinflammation directly. The lower the S-Ado/SAICAr ratio in cerebrospinal fluid, the more severe the clinical outcome, suggesting differential toxicity of SAICAr relative to S-Ado.

GO terms: Complement activation, alternative pathway (GO:0006957), Inflammatory response (GO:0006954), Blood-brain barrier maintenance (GO:0035633)

Protein Dysfunction

The ADSL protein functions as a homotetramer. Most pathogenic missense mutations impair: - Protein folding and stability of the tetramer - Catalytic activity at the active site - Susceptibility to oxidative damage: The P100A substitution distorts domain I near the catalytic His-86 residue and may expose Cys-98/Cys-99 to oxidizing agents (PMID: 15571240) - All mutant enzymes display a proportional decrease in activity against both substrates (PMID: 10888601)

Metabolic Changes

Primary metabolic abnormalities: - Elevated in body fluids: SAICAr (CHEBI:141525), S-Ado (CHEBI:99039) - Depleted: AMP (CHEBI:16027), ATP (CHEBI:15422), GMP, GTP (purine nucleotides) - Reduced fumarate production (product of ADSL reaction) - Energy metabolism: Secondary mitochondrial dysfunction leading to impaired oxidative phosphorylation and reduced ATP

Immune System Involvement

• Activation of the alternative complement pathway (PMID: 40896413)
• Neuroinflammation driven by SAICAr-mediated complement activation
• Blood-brain barrier disruption
• Progressive neurodegeneration via immune-mediated mechanisms
• GO terms: Complement activation (GO:0006956), Inflammatory response (GO:0006954)

Tissue Damage Mechanisms

• Neurotoxicity from accumulated SAICAr
• Hypomyelination/dysmyelination secondary to oligodendrocyte damage: "Hypo/dysmyelination seemed to be secondary to damage of oligodendroglia and axons of damaged neuronal cells" (PMID: 20054783)
• Axonal damage secondary to neuronal injury
• Cerebral and cerebellar atrophy
• White matter loss (supra- and infratentorial) (PMID: 21625931)
• Oxidative stress vulnerability of mutant ADSL protein (PMID: 15571240)

Cell Types Involved

• Neurons (CL:0000540) -- primary target of neurotoxicity
• Oligodendrocytes (CL:0000128) -- damaged, leading to hypomyelination/dysmyelination
• Astrocytes (CL:0000127) -- potential neuroinflammatory mediators, reactive gliosis
• Microglia (CL:0000129) -- complement-mediated activation

Molecular Profiling

CRISPR models: CRISPR-Cas9 genome-edited HeLa cells deficient in individual DNPS steps showed accumulation of the substrate for the knocked-out enzyme and reduced purinosome formation (PMID: 27590927).

Cancer context: ADSL has been identified as a potential oncogenic driver in hepatocellular carcinoma. "CRISPR-mediated knockout of ADSL impaired colony formation of liver cancer cells by affecting AMP production... ADSL knockout caused S-phase cell cycle arrest not by inducing DNA damage but by impairing mitochondrial function" (PMID: 33336367).

7. Anatomical Structures Affected

Organ Level

Body systems involved: Nervous system (primary), musculoskeletal system (secondary), respiratory system (neonatal form)

Tissue and Cell Level

• White matter (UBERON:0002316): Hypomyelination, dysmyelination, abnormal signal
• Gray matter (UBERON:0001870): Cortical atrophy
• Cerebellar cortex (UBERON:0002129): Atrophy
• Corpus callosum (UBERON:0002336): Atrophy
• Cerebellar vermis (UBERON:0004720): Atrophy

Neuropathological findings revealed "damage of all cellular elements of brain tissue" (PMID: 20054783).

Cell populations affected: - Neurons (CL:0000540) -- neurotoxicity, degeneration - Oligodendrocytes (CL:0000128) -- impaired myelination - Microglia (CL:0000129) -- neuroinflammatory activation - Astrocytes (CL:0000127) -- reactive gliosis

Subcellular Level

• Cytosol (GO:0005829): Site of purinosome assembly and ADSL activity
• Mitochondria (GO:0005739): Secondary dysfunction, fragmentation (PMID: 40914938)
• Nucleus (GO:0005634): Impaired nucleotide supply for DNA/RNA synthesis
• Purinosome complex (GO:0032991)

Localization

Anatomical sites (UBERON terms): - Cerebral cortex (UBERON:0000956) -- atrophy - Cerebellum (UBERON:0002037) -- hypoplasia, atrophy - Corpus callosum (UBERON:0002336) -- atrophy - Lateral ventricles (UBERON:0002285) -- widening - Cisterna magna (UBERON:0003028) -- enlargement

Lateralization: Bilateral, symmetric involvement of brain structures.

8. Temporal Development

Onset

• Typical age of onset: 89.2% of patients present within the first year of life (PMID: 37842880)
• Fatal neonatal form: Birth to first days
• Type I: First weeks to months (median 0.63 years)
• Type II: Months to first years; rare late-onset cases diagnosed in childhood or adolescence

First signs: psychomotor delay (8/18 patients), epilepsy (3/18), combined (3/18), or other neurological signs including apneas, hypotonia, nystagmus (PMID: 33648541)

HPO terms: Infantile onset (HP:0003593), Neonatal onset (HP:0003623), Childhood onset (HP:0011463)

Diagnostic Delay

The median age at diagnosis (6.4 years) significantly lags behind the median age of onset (0.63 years), indicating substantial diagnostic delay. Seven of 18 patients in one series were diagnosed by exome sequencing, highlighting the role of genomic testing in overcoming diagnostic delays (PMID: 33648541).

Progression

• Neonatal form: Rapid, lethal within weeks
• Type I: Progressive neurological deterioration over years; some patients develop late-onset spasticity and thoracic deformity (PMID: 21903433)
• Type II: Slow progression; some patients show relative stability or even mild improvement. One patient "began to walk independently at the age of 3 years. From the age of 4 years, her communication skills improved and she presented fewer autistic features" (PMID: 23504561)

Disease duration: Chronic lifelong (types I and II); self-limited by death (neonatal form)

Critical Periods

• Early therapeutic intervention (younger, less cognitively impaired patients) shows better response to allopurinol treatment (PMID: 41053929)
• D-ribose withdrawal precipitated status epilepticus and acute neurological deterioration, representing a critical vulnerability window (PMID: 21903433)

9. Inheritance and Population

Epidemiology

• Prevalence: ~0.00125 per 100,000 (ultra-rare) (PMID: 40896413)
• Total cases reported: >80-100 individuals worldwide; 88 patients identified in systematic literature review (PMID: 37842880)
• Incidence: Unknown precisely; likely underdiagnosed due to nonspecific clinical presentation (PMID: 28768552)
• A Czech screening program over 13 years identified 8 patients with ADSL deficiency out of approximately 1,600 patients screened for purine/pyrimidine disorders (PMID: 24940674)

Genetic Inheritance

• Inheritance pattern: Autosomal recessive (AR)
• Penetrance: Complete -- all individuals with biallelic pathogenic variants manifest disease
• Expressivity: Highly variable, determined by residual enzyme activity and protein stability
• Genetic anticipation: Not observed (not a repeat expansion disorder)
• Germline mosaicism: Not documented
• Consanguinity: Present in a significant proportion of reported families, consistent with AR inheritance; homozygous mutations (e.g., p.R426H, p.D430N) common in consanguineous families
• Carrier frequency: Unknown due to rarity; expected to be very low
• Founder effects: The p.R426H variant is the most common globally (19/88 patients homozygous), suggesting possible founder effect or recurrent mutation at a CpG site

Population Demographics

• Affected populations: No specific ethnic predisposition established; cases reported across diverse ethnic groups including European, Middle Eastern, Asian, South American, and African populations
• Geographic distribution: Worldwide, with larger case series from Belgium, Poland, Czech Republic, Italy, Spain, and Brazil
• Sex ratio: 12 males to 6 females in one cohort (PMID: 33648541), though this may reflect ascertainment bias; no inherent sex predisposition expected for AR disorder
• Age distribution: Predominantly pediatric; survival to adulthood is possible in type II

10. Diagnostics

Clinical Tests

Biochemical Tests (Primary Diagnostic Approach)

Urinary Succinylpurine Analysis (Gold Standard):

Methods: - Bratton-Marshall test: Traditional colorimetric screening assay for SAICAr in urine (PMID: 12368987) - HPLC with diode-array detection (HPLC-DAD): More sensitive and specific - LC-MS/MS: Gold standard; also detects deribosylated metabolites SAICA and SA

CRITICAL CAVEAT: False-negative screening can occur due to bacterial deribosylation of urinary biomarkers. "Screening methods for the diagnosis of dADSL may be falsely negative due to bacteria-mediated deribosylation of SAICA-riboside and SAdo" (PMID: 24183879). HPLC-DAD or LC-MS/MS methods that simultaneously detect ribosylated and deribosylated forms should be used preferentially.

Enzyme Activity Assay: ADSL enzyme activity can be measured in red blood cells, lymphocytes, or cultured fibroblasts. Reduced activity confirms the diagnosis.

Biomarkers: - SAICAr -- primary diagnostic biomarker - S-Ado -- primary diagnostic biomarker - S-Ado/SAICAr ratio -- prognostic biomarker (value debated, PMID: 20127976) - SAICA and SA (deribosylated forms) -- may be detected in urines with bacterial contamination

Imaging Studies

Brain MRI (PMID: 21625931; PMID: 20054783): - Delayed or absent myelination - White matter signal abnormalities (T2 hyperintensity) - Cerebral and cerebellar atrophy - Corpus callosum atrophy - Enlarged ventricles and subarachnoid spaces - Note: MRI may be normal in mild cases (PMID: 28768552)

Electrophysiology

EEG (PMID: 37842880): - Poor background organization with theta-delta slowing - Hypsarrhythmia (in infantile spasms) - Multifocal epileptiform discharges

Genetic Testing

Recommended approach: 1. First-line: Biochemical screening (urinary succinylpurines by HPLC-DAD or LC-MS/MS) 2. Confirmatory: ADSL gene sequencing 3. Alternative route: Whole exome sequencing (WES) -- increasingly used; diagnosed 7/18 patients in one cohort (PMID: 33648541)

• WES utility: High -- effective for diagnosis, especially in patients with nonspecific neurological presentations (PMID: 28768552)
• Gene panels: Included in metabolic disease, epilepsy, and intellectual disability gene panels
• Single gene testing: ADSL sequencing with deletion/duplication analysis
• CMA/Karyotyping/FISH: Not typically informative (point mutations, not structural variants)

Clinical Criteria

Diagnostic criteria: 1. Clinical presentation with neurological features (developmental delay, seizures, autistic features) 2. Biochemical confirmation: elevated SAICAr and S-Ado in urine, plasma, or CSF 3. Genetic confirmation: biallelic pathogenic variants in ADSL 4. Optional: reduced ADSL enzyme activity in erythrocytes or fibroblasts

Differential Diagnosis

Screening

• Newborn screening: Not currently included in standard newborn screening panels in most countries
• Selective screening: Recommended for patients with unexplained neonatal seizures, epileptic encephalopathy, developmental delay, or autistic features. "A search for this disorder should be included in the screening program of children with unexplained neonatal seizures or severe infantile epileptic encephalopathy" (PMID: 11392513)
• Cascade screening: Recommended for siblings of affected individuals
• Prenatal diagnosis: Possible through molecular analysis of ADSL variants in chorionic villus samples or amniocytes

11. Outcome/Prognosis

Survival and Mortality

• Fatal neonatal form: Death within days to weeks of life; universally lethal. Primary cause of death is respiratory failure and intractable seizures.
• Type I (severe): Significantly reduced life expectancy; many patients survive into childhood or adolescence but with severe disability. Status epilepticus and complications of severe neurological disability contribute to mortality.
• Type II (mild/moderate): Life expectancy may approach normal; patients survive into adulthood.
• Overall mortality: No formal survival statistics available due to rarity.

Morbidity and Function

• Type I: Severe intellectual disability, dependent on caregivers for all activities of daily living, drug-resistant epilepsy, progressive spasticity
• Type II: Mild to moderate intellectual disability; some patients attend special education, develop limited communication skills. One patient "began to make statements that form a logical continuity and make progress in simple manual operations" (PMID: 23504561)

Complications

• Drug-resistant epilepsy and status epilepticus
• Progressive spasticity and contractures
• Thoracic deformity (PMID: 21903433)
• Aspiration pneumonia (in severely affected patients)
• Nutritional challenges and growth failure
• Acute neurological deterioration (particularly associated with D-ribose withdrawal)

Prognostic Factors

12. Treatment

Current Standard of Care

No curative treatment exists. Management is primarily supportive. "Currently, no effective treatment is available for adenylosuccinate lyase deficiency" (PMID: 11392513).

Pharmacotherapy

Allopurinol (Zyloric) -- MAXO:0001298

The most promising pharmacological intervention to date. A Phase II prospective trial reported: "Results showed clinical improvements in younger, less cognitively impaired patients, indicated by better Vineland Adaptive Behavior Scale (VABS II) scores and reduced hyperactivity on the Aberrant Behavior Checklist (ABC) and Conners Rating Scale-Revised (CRSR). These improvements correlated with significant decreases in urinary SAICAr levels and an increased S-Ado/SAICAr ratio" (PMID: 41053929).

• Dose: 10-20 mg/kg/day (max 400 mg/day children, 900 mg/day adults)
• Participants: 8 patients (4 children, 4 young adults)
• Responders: Younger, less cognitively impaired patients
• Non-responders: Older or more severely affected patients
• Mechanism: Xanthine oxidase inhibitor; potentially redirects purine salvage and reduces toxic metabolite accumulation
• Critical finding: Suggests a therapeutic window where early intervention is key

Anti-epileptic Drugs (AEDs) -- MAXO:0000756

• Multiple AEDs used for seizure control; no specific AED is preferentially effective
• Many patients have drug-resistant epilepsy requiring polytherapy
• Various AEDs documented across case series without clear superiority

Ketogenic Diet -- MAXO:0001193

One case report documented a positive effect on seizure control in a type II patient (PMID: 23504561).

D-Ribose (CAUTION)

D-ribose supplementation was trialed but showed no clinical benefit. "D-ribose must be considered with caution as, in our experience, it returns no clinical benefit and drug withdrawal can precipitate status epilepticus and acute neurological deterioration" (PMID: 21903433).

Advanced Therapeutics

Gene Therapy

No gene therapy trials are currently registered for ADSLD. However, the monogenic nature of the disease and the relatively small gene size make it a potential candidate for AAV-mediated gene replacement therapy. Identified as an "urgent need" (PMID: 40896413).

Targeting Mitochondrial Dysfunction

The identification of ADSLD as a secondary mitochondrial disease opens avenues for: - Overexpression of constitutively active ERK2 partially rescues the mitochondrial phenotype (PMID: 40914938) - Purine intermediate supplementation partially rescues mitochondrial function - Mitochondrial-targeted therapies (e.g., CoQ10, idebenone) - ERK2/AKT pathway modulators

Complement Pathway Inhibition

The emerging role of complement-mediated neuroinflammation suggests potential for complement inhibitors (e.g., eculizumab, avacopan) as neuroprotective agents (PMID: 40896413).

Supportive and Rehabilitative Care

• Physical therapy / physiotherapy (MAXO:0000011)
• Occupational therapy (MAXO:0000536)
• Speech therapy (MAXO:0000930)
• Hydrotherapy, Hippotherapy, Pet therapy, Music therapy (PMID: 23504561)
• Nutritional support for feeding difficulties
• Special education services

Treatment Strategy

Current management algorithm: 1. Seizure control (AEDs, ketogenic diet if refractory) 2. Developmental support (multidisciplinary rehabilitation) 3. Nutritional management 4. Consider allopurinol trial, especially in younger patients with milder phenotype 5. Monitor succinylpurine levels in urine/plasma to assess treatment response 6. Avoid D-ribose

13. Prevention

Primary Prevention

• Genetic counseling (MAXO:0000079): Recommended for families with affected individuals; 25% recurrence risk for carrier parents
• Preimplantation genetic diagnosis (PGD): Available for families with known pathogenic variants
• Prenatal diagnosis: Molecular analysis of ADSL variants in chorionic villi or amniotic fluid cells
• Carrier testing: Available for at-risk family members

Secondary Prevention (Early Detection)

• Selective metabolic screening: Recommended for patients with unexplained neonatal seizures, epileptic encephalopathy, developmental delay, or autistic features. "ADSL deficiency should be part of the screening to be performed in case of neonatal seizures" (PMID: 18201882)
• Bratton-Marshall test: Colorimetric urine screening test for SAICAr (PMID: 12368987)
• WES/WGS: Increasingly used for undiagnosed neurological disorders, enabling earlier diagnosis
• Cascade screening: Siblings of affected patients should be tested
• Caution: Fresh urine samples required to avoid false negatives from bacterial deribosylation (PMID: 24183879)

Tertiary Prevention

• Seizure management to prevent secondary brain injury
• Nutritional support to prevent malnutrition
• Physical therapy to prevent contractures
• Allopurinol therapy (particularly in younger patients) to potentially slow disease progression
• Avoidance of D-ribose based on adverse outcomes (PMID: 21903433)

Immunization

Not applicable. ADSLD is not an infectious or immune-mediated disease.

14. Other Species / Natural Disease

Orthologous Genes

The ADSL gene is highly conserved across species, reflecting the fundamental importance of purine metabolism:

Natural Disease in Other Species

No naturally occurring ADSL deficiency has been reported in domestic or wild animal species. This may reflect: - Embryonic lethality of complete loss-of-function in other species - Lack of diagnostic awareness in veterinary medicine - True absence of naturally occurring disease-causing variants

Comparative Biology

The ADSL enzyme and purine de novo synthesis pathway are evolutionarily conserved from yeast to humans. The S. cerevisiae homolog ADE13 has been used extensively to study ADSL biochemistry. The Drosophila ortholog raspberry (ras) has been used as a model to study purine metabolism.

The conservation of disease mechanisms across species supports the use of model organisms for understanding ADSLD pathophysiology. Conservation of both catalytic reactions suggests fundamental importance in purine metabolism.

Transmission

Not applicable. ADSLD is a genetic disorder, not an infectious disease. No zoonotic potential or cross-species susceptibility considerations.

15. Model Organisms

Available Models

Key Model Findings

1. Patient fibroblasts: Demonstrated that "various mutations of ATIC and ADSL destabilize to various degrees of purinosome assembly" and "the ability to form purinosomes correlates with clinical phenotypes of individual ADSL patients" (PMID: 22180458)

2. CRISPR HeLa models: "In all model cell lines with the exception of one, an accumulation of the substrate(s) for the knocked out enzyme was identified. The ability to form the purinosome was reduced" (PMID: 27590927). These models also enabled development of diagnostic LC-MS/MS methods.

3. Liver cancer cells (ADSL-KO): "CRISPR-mediated knockout of ADSL impaired colony formation of liver cancer cells by affecting AMP production... ADSL knockout caused S-phase cell cycle arrest not by inducing DNA damage but by impairing mitochondrial function" (PMID: 33336367). In vivo xenograft models showed retarded tumor growth.

4. Mitochondrial studies: Patient-derived cells demonstrated increased mitochondrial fragmentation, impaired respiration, and reduced ATP production, with defects linked to ERK2/AKT suppression (PMID: 40914938).

Model Limitations

• No established animal models (mouse knockout, zebrafish morphant) are widely used for ADSLD research
• Complete ADSL knockout is likely embryonically lethal, necessitating conditional or hypomorphic approaches
• Cell-based models cannot fully recapitulate the neurological phenotype
• Cancer cell lines (HeLa, HCC) may not reflect neuronal pathophysiology
• The blood-brain barrier and CNS-specific effects are difficult to study in vitro
• No validated animal model fully recapitulates the human neurological phenotype

Proposed Models

Knock-in mice carrying human pathogenic mutations (e.g., equivalent of p.R426H) have been proposed but not yet widely reported. Development of conditional knock-in mouse models and iPSC-derived cerebral organoids are critical research priorities.

Key Findings

Finding 1: ADSLD is an Ultra-Rare Autosomal Recessive Purine Metabolism Disorder

ADSLD has a global prevalence of approximately 0.00125 per 100,000, with more than 80 patients identified worldwide. The ADSL gene on chromosome 22q13.1 consists of 13 exons spanning 23 kb. Three clinical phenotypes are recognized: fatal neonatal, type I (severe), and type II (moderate/mild). Disease onset occurs within the first year of life in 89.2% of cases, and epilepsy is present in 81.8% of patients. This was established through systematic literature review covering 88 patients (PMID: 40896413; PMID: 37842880; PMID: 25112391).

Finding 2: ADSLD is a Secondary Mitochondrial Disease with ERK2/AKT Signaling Involvement

Recent research (2025) established that ADSLD causes secondary mitochondrial dysfunction, including increased mitochondrial fragmentation, impaired respiration, and reduced ATP production. "The severity of mitochondrial impairment correlates with ADSLd pathology, especially in mitochondria-dependent tissues" (PMID: 40914938). This dysfunction is mediated through suppression of ERK2 and AKT signaling pathways, and can be partially rescued by overexpressing constitutively active ERK2 or supplementing purine intermediates. This finding reframes ADSLD not just as a purine metabolism disorder but as a mitochondrial disease, with implications for therapy.

Finding 3: Complement Pathway Activation Drives Neuroinflammation

Activation of the alternative complement pathway has been identified as "a key driver of inflammation, blood-brain barrier disruption, and progressive neurodegeneration" (PMID: 40896413). SAICAr, the more neurotoxic succinylpurine, promotes neuroinflammation, and lower S-Ado/SAICAr ratios correlate with more severe clinical outcomes. This emerging hypothesis provides a mechanistic link between metabolite accumulation and the progressive neurodegeneration seen in ADSLD.

Finding 4: Allopurinol Shows Clinical Benefit in Young ADSLD Patients

A Phase II prospective trial of allopurinol (10-20 mg/kg/day) in 8 patients (4 children, 4 young adults) demonstrated clinical improvements in younger, less cognitively impaired patients. "These improvements correlated with significant decreases in urinary SAICAr levels and an increased S-Ado/SAICAr ratio" (PMID: 41053929). No changes were observed in older or more severely affected patients, suggesting a critical therapeutic window for intervention.

Finding 5: Purinosome Assembly Disruption Correlates with Clinical Severity

ADSL mutations destabilize purinosome assembly in patient fibroblasts, and the degree of purinosome disruption correlates with clinical phenotype severity (PMID: 22180458). Furthermore, "phenotypic severity in ADSL deficiency is correlated with residual enzymatic activity and structural stability of the corresponding mutant ADSL complexes" (PMID: 20127976). This establishes a robust genotype-phenotype correlation framework: variant → protein stability → enzyme activity → purinosome integrity → clinical phenotype.

Mechanistic Model

The pathophysiology of ADSLD can be understood as a cascade of interconnected molecular events operating through multiple parallel and converging pathways:

    ADSL Gene Mutations (biallelic)
              |
    Reduced Enzyme Activity
    & Protein Instability
              |
       +--------------+---------------+
       |                              |
     TOXIC ACCUMULATION              PURINE DEPLETION
     (SAICAr, S-Ado)                (↓AMP, ↓ATP, ↓GTP)
       |                              |
     +---------+---------+          +---------+---------+
     |                   |          |                   |
  SAICAr            S-Ado      Mitochondrial      ↓DNA/RNA
  neurotoxicity     (less     dysfunction         synthesis
     |              toxic)        |
     |                        Fragmentation
  Complement                  ↓Respiration
  activation                  ↓ATP
  (alternative)                   |
     |                        ERK2/AKT
  BBB disruption              suppression
     |                            |
  Neuroinflammation          Cell growth/
     |                       survival impairment
     |                            |
     +------------+---------------+
  |
 PROGRESSIVE NEURODEGENERATION
 • White matter loss / dysmyelination
 • Cortical & cerebellar atrophy
 • Seizures / epilepsy
 • Developmental delay / intellectual disability
 • Autistic features

This model highlights three key therapeutic intervention points: 1. Upstream: Reduce SAICAr accumulation (allopurinol) 2. Midstream: Rescue mitochondrial function (ERK2 activation, purine supplementation) 3. Downstream: Block complement-mediated neuroinflammation (complement inhibitors)

Evidence Base

Limitations and Knowledge Gaps

1. Ultra-rare disease limitations: With fewer than 100 identified patients worldwide, all clinical data come from small case series and single case reports, limiting statistical power and generalizability.

2. Lack of animal models: No well-characterized animal model of ADSLD exists, hindering preclinical therapeutic development and detailed mechanistic studies of CNS pathology.

3. Incomplete genotype-phenotype correlation: While residual enzyme activity and tetramer stability explain much of the phenotypic variation, the discordance between in vitro activity against both substrates and the differential accumulation of SAICAr vs. S-Ado in CSF remains unexplained. As noted: "All the mutant enzymes studied in vitro displayed a proportional decrease in activity against both of their substrates. However, this was not concordant with strikingly different concentration ratios in the CSF of individual patients" (PMID: 10888601).

4. Complement pathway hypothesis: The role of complement activation in neuroinflammation is still an emerging hypothesis that requires validation in patient samples and model systems.

5. Treatment evidence: The allopurinol trial included only 8 patients without a placebo control; larger, randomized trials are needed to confirm efficacy.

6. No newborn screening: ADSLD is not included in standard newborn screening panels, contributing to diagnostic delays averaging ~6 years.

7. Long-term natural history: Limited longitudinal data on disease progression, especially for mild type II patients who may survive into adulthood.

8. Epigenetic and modifier gene effects: No studies have examined epigenetic modifications or genetic modifiers that might influence disease severity.

9. Neurotoxicity mechanisms: The exact molecular mechanisms by which SAICAr exerts neurotoxicity and activates complement remain to be elucidated.

10. Quality of life data: No formal quality-of-life assessments using validated instruments have been published.

Proposed Follow-up Experiments and Actions

Near-Term (1-3 years)

1. Develop conditional knock-in mouse model carrying common human ADSL mutations (e.g., p.R426H) with CNS-specific expression to study neuropathology and test therapeutic interventions in vivo.

2. Validate the complement pathway hypothesis using patient CSF samples and post-mortem brain tissue to measure complement activation markers (C3a, C5a, MAC) and correlate with disease severity.

3. Conduct a larger, multi-center, randomized controlled trial of allopurinol in ADSLD patients, stratifying by age, severity, and genotype to identify optimal treatment windows and confirm Phase II findings.

4. Perform multi-omics profiling (transcriptomics, proteomics, metabolomics) on patient-derived iPSC-differentiated neurons to comprehensively characterize molecular disruptions specific to the neuronal context.

5. Develop iPSC-derived cerebral organoid models to study ADSLD-associated neurodevelopmental defects and test candidate therapies in a 3D human brain model.

Medium-Term (3-5 years)

1. Evaluate complement inhibitors (e.g., anti-C5 antibodies, factor B inhibitors) in ADSLD cell and animal models as potential neuroprotective therapies.

2. Test mitochondrial-targeted therapies (CoQ10, idebenone, NAD+ precursors, ERK2/AKT pathway activators) in ADSLD models and patients.

3. Investigate AAV-mediated gene therapy for ADSLD, determining optimal serotype, promoter, and route of administration for CNS delivery.

4. Advocate for inclusion of ADSLD in newborn screening panels using tandem mass spectrometry-based detection of SAICAr and S-Ado, potentially reducing the current 6-year diagnostic delay.

Long-Term (5+ years)

1. Establish an international ADSLD patient registry with standardized clinical assessments, longitudinal follow-up, and biobanking to enable natural history studies and clinical trials.

2. Develop biomarker-guided personalized treatment protocols based on S-Ado/SAICAr ratios, residual enzyme activity, and genotype.

3. Explore gene editing approaches (base editing, prime editing) to correct specific ADSL point mutations in patient cells, potentially offering mutation-specific therapeutic strategies.

Ontology Term Summary

Report generated: 2026-05-05 Based on systematic review of 31 published papers and disease database entries Comprehensive disease characterization covering 15 knowledge domains